PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Pharmaceutical company Sandoz has entered into a partnership with Indian biopharmaceutical Biocon to develop biosimilars for use in immunology and oncology.
Through its new partnership with Biocon, Sandoz will now develop a range of next-generation biosimilars. According to a statement announcing the partnership, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals.
They will also have a cost and profit share arrangement globally, in which Sandoz will be responsible for commercialization in the US, Canada and the EU (including EFTA and Balkan states), while Biocon will lead commercialization in the rest of the world.
“Today’s announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future,” said Sandoz CEO Richard Francis.
Carol Lynch, global head of biopharmaceuticals at Sandoz, believes that the cooperation with Biocon will strengthen the company’s ability to deliver next-generation biosimilar medicines to patients.
“Together, we will be able to realize benefits at every stage of the value chain, from development, through manufacturing to commercialization.”
Biocon is the largest biopharmaceutical company in India. It commercialized medicines in India, Japan and a few emerging markets and was the first Indian company to have a biosimilar approved by the U.S. Food and Drug Administration.